Nocturnal/Diurnal Intraocular Pressure-Lowering Effect of Netarsudil Ophthalmic Solution

Completed · Phase 2

Conditions studied: Ocular Hypertension, Open Angle Glaucoma

In brief

To evaluate effect of Netarsudil Ophthalmic Solution 0.02% on Nocturnal and Diurnal Intraocular Pressure.

Key facts

Study ID

NCT02874846

Run by

Aerie Pharmaceuticals

People needed

12

Starts

2016-07-01

Expected to finish

2016-09-01

Last updated by the study team

2018-04-17

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• 18 years of age or older.
• Ocular hypertension or open-angle glaucoma in both eyes.
• Unmedicated intraocular pressure > 17 mmHg in one or both eyes and < 30 mmHg in both eyes.
• Corrected visual acuity in each eye equivalent to 20/200 or better.
• Able and willing to give signed informed consent and follow study instructions.

You may not qualify if…

• Glaucoma with pseudoexfoliation or pigment dispersion component, history of angle closure, narrow angles.
• Intraocular pressure ≥ 30 mmHg.
• Use of ocular medications within 30 days.
• Known hypersensitivity to any component of the test formulations or to medications used routinely during a clinical eye examination.
• Previous eye surgery (other than cataract).
• Ocular trauma within 6 months.
• Clinically significant ocular disease that might interfere with the study.
• Central corneal thickness greater than 620 µm.

Where it is running

• Nancy Ramirez — Bedminster, New Jersey, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.